# Lisa Licitra

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lisa-licitra/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,731 |
| Field | Head and Neck Cancer Studies |
| h-index | 87 |
| i10-index | 350 |
| Last Known Institution | University of Milan |
| OpenAlex ID | https://openalex.org/A5047193688 |
| ORCID iD | https://orcid.org/0000-0003-0623-4118 |
| Works | 945 |

## Researcher papers

- [Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck](https://scholariq.org/papers/nivolumab-for-recurrent-squamous-cell-carcinoma-of-the-head-and-neck/)
- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)
- [Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression](https://scholariq.org/papers/nivolumab-vs-investigator-s-choice-in-recurrent-or-metastatic-squamous-cell/)
- [Management of Salivary Gland Malignancy: ASCO Guideline](https://scholariq.org/papers/management-of-salivary-gland-malignancy-asco-guideline/)
- [Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group](https://scholariq.org/papers/meta-analysis-of-chemotherapy-in-head-and-neck-cancer-mach-nc-an-update-on-107/)
- [Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy](https://scholariq.org/papers/phase-3-randomized-trial-on-larynx-preservation-comparing-sequential-vs/)
- [Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial](https://scholariq.org/papers/cemiplimab-in-locally-advanced-basal-cell-carcinoma-after-hedgehog-inhibitor/)
- [Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data](https://scholariq.org/papers/weekly-low-dose-versus-three-weekly-high-dose-cisplatin-for-concurrent/)

## Researcher topics

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Salivary Gland Tumors Diagnosis and Treatment](https://scholariq.org/topics/salivary-gland-tumors-diagnosis-and-treatment/)
- [Head and Neck Surgical Oncology](https://scholariq.org/topics/head-and-neck-surgical-oncology/)

## Researcher university

- [University of Milan](https://scholariq.org/institutions/university-of-milan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.